Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study).

Nagata N, Maeda H, Ishibashi K, Hirata K, Makiyama A, Iwamoto S, Takemoto H, Imasato M, Yoshida Y, Munemoto Y, Tanaka C, Morita Y, Hotta Y, Toyofuku A, Nagasaka T, Morita S, Sakamoto J, Mishima H

Open source

DOI: 10.1007/s12032-019-1254-4
Published: 2019 Apr 24
Container: Medical oncology (Northwood, London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12032-019-1254-4,
  title = {Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study).},
  author = {Nagata N and Maeda H and Ishibashi K and Hirata K and Makiyama A and Iwamoto S and Takemoto H and Imasato M and Yoshida Y and Munemoto Y and Tanaka C and Morita Y and Hotta Y and Toyofuku A and Nagasaka T and Morita S and Sakamoto J and Mishima H},
  year = {2019},
  journal = {Medical oncology (Northwood, London, England)},
  doi = {10.1007/s12032-019-1254-4},
  url = {https://doi.org/10.1007/s12032-019-1254-4}
}

RIS

TY  - JOUR
TI  - Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study).
AU  - Nagata N
AU  - Maeda H
AU  - Ishibashi K
AU  - Hirata K
AU  - Makiyama A
AU  - Iwamoto S
AU  - Takemoto H
AU  - Imasato M
AU  - Yoshida Y
AU  - Munemoto Y
AU  - Tanaka C
AU  - Morita Y
AU  - Hotta Y
AU  - Toyofuku A
AU  - Nagasaka T
AU  - Morita S
AU  - Sakamoto J
AU  - Mishima H
PY  - 2019
JO  - Medical oncology (Northwood, London, England)
DO  - 10.1007/s12032-019-1254-4
UR  - https://doi.org/10.1007/s12032-019-1254-4
ER  -

APA

N, N., H, M., K, I., K, H., A, M., S, I., H, T., M, I., Y, Y., Y, M., C, T., Y, M., Y, H., A, T., T, N., S, M., J, S., & H, M. (2019). Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study).. Medical oncology (Northwood, London, England). https://doi.org/10.1007/s12032-019-1254-4

Source records

pubmed · retrieved 2026-09-26T11:01:33.133Z